In this issue:
Tandem high-dose influenza vaccination beneficial for patients with PCDs
Rheumatologic diseases impact the risk of MGUS progression
Panobinostat/carfilzomib shows promise for RRMM
Bortezomib, vorinostat and dexamethasone combination therapy in relapsed myeloma
Front-line VCD chemotherapy in elderly, transplant-ineligible patients
Cost-effectiveness of novel treatment sequences for transplant-ineligible patients
Quality of control groups in randomised trials of MM require scrutiny
Myeloma XI+ reports PFS results for induction KRdc in a transplant-eligible cohort
Psychological distress may negatively impact survival
Preclinical evaluation of a novel engineered T-cell product, Descartes-08, for MM
Please login below to download this issue (PDF)